New development on HPV prophylactic vaccine

• OC 06-01 • Analysis of immunogenicity of the 9-valent HPV vaccine based on five clinical trials See abstract > A. Alain Luxembourg • OC 06-02 • Induction of immune memory following administration of the 9-valent HPV vaccine See abstract > E. Elmar Joura • OC 06-03 • Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine See abstract > O-E. Ole-Erik Iversen • OC 06-04 • Use of the nonavalent HPV vaccine in previously vaccinated individuals See abstract > M. Margaret Stanley • OC 06-05 • EVALUATION OF THE INDIVIDUAL RESIDUAL RISK OF CERVICAL CANCER AFTER VACCINATION WITH GARDASIL 9. See abstract > C. Chris Meijer • OC 06-06 • Sustained non-inferiority of immune response to 2-dose schedules 0,6 and 0,12 months (M) versus 3 doses 0,1,6 M of HPV-16/18 AS04-adjuvanted vaccine; End of study analysis of a randomized trial See abstract > N. Nicolas Folschweiller • OC 06-07 • Description of IGA/IGG immune responses during three doses of the HPV-16/18 ASO4-adjuvanted vaccine See abstract > A. Ana Katherine Gonçalves • OC 06-08 • Cross-protection & population effect of HPV vaccines from the perspective of real-world impact data See abstract > G. Gonzalo Perez • OC 06-09 • 60 month follow up of a two dose HPV-4 vaccine schedule; results from a phase III post-licensure randomized trial See abstract > S. Simon Dobson • OC 06-10 • Sustained antibody responses six years following reduced dose quadrivalent HPV vaccine in adolescent Fijian girls See abstract > Z. Zheng Quan Ryan Toh • OC 06-11 • Cost-effectiveness evaluation of the quadrivalent HPV vaccination program for females age 9-10 years in Costa Rica See abstract > M. Megan O'Brien